glofitamab,Obinutuzumab 
roche
['glofitamab', 'dlbcl', 'lymphoma', 'roche']
 updates:
at the ongoing #asco 2022 #conference, #roche showcased noteworthy results from the phase ii expansion study of #glofitamab in the patients with r/r diffuse large b-cell lymphoma (#dlbcl). get more insights at: #asco22 #asco2022 #lymphoma 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry